ArticleBritish journal of cancer2012
Identification of markers of prostate cancer progression using candidate gene expression.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- AAA ATPase TRIP13 is overexpressed in prostate cancer and promotes tumor progression.Translational oncology · 2026Article
- Analysis of qPCR Data: From PCR Efficiency to Absolute Target Quantity.International journal of molecular sciences · 2025Review
- Genomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active Surveillance.The Prostate · 2025Article
- Functional and structural characterization of the human indolethylamine N-methyltransferase through fluorometric, thermal and computational docking analyses.Biology direct · 2025Article
- Integrating Radiosensitivity Index and Radiation Resistance Related Index Improves Prostate Cancer Outcome Prediction.Advances in radiation oncology · 2025Article
- Cellular Signaling of Amino Acid Metabolism in Prostate Cancer.International journal of molecular sciences · 2025Review
- From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine.Health information science and systems · 2024Review
- β-hydroxybutyrate inhibits malignant phenotypes of prostate cancer cells through β-hydroxybutyrylation of indoleacetamide-N-methyltransferase.Cancer cell international · 2024Article
- [TRIP13 Enhances Radioresistance of Lung Adenocarcinoma Cells through the Homologous Recombination Pathway].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Article
- TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage.Cancer medicine · 2023Article
- TRIP 13-dependent pathways promote the development of gastric cancer.Functional & integrative genomics · 2023Article
- Development and validation of a selenium metabolism regulators associated prognostic model for hepatocellular carcinoma.BMC cancer · 2023Article
- An Investigation of the Prognostic Role of Genes Related to Lipid Metabolism in Head and Neck Squamous Cell Carcinoma.International journal of genomics · 2023Article
- PTEN Protein Phosphatase Activity Is Not Required for Tumour Suppression in the Mouse Prostate.Biomolecules · 2022Article
- Indolethylamine-N-Methyltransferase Inhibits Proliferation and Promotes Apoptosis of Human Prostate Cancer Cells: A Mechanistic Exploration.Frontiers in cell and developmental biology · 2022Article
- Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma.Frontiers in genetics · 2022Article
- Poor prognosis, hypomethylation, and immune infiltrates are associated with downregulation of INMT in head and neck squamous cell carcinoma.Frontiers in genetics · 2022Article
- Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer.Journal of experimental & clinical cancer research : CR · 2021Article
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.The Journal of clinical investigation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic prostate cancer (PCa) has no curative treatment options. Some forms of PCa are indolent and slow growing, while others metastasise quickly and may prove fatal within a very short time. The basis of this variable prognosis is poorly understood, despite considerable research. The aim of this study was to identify markers associated with the progression of PCa.
methodsArtificial neuronal network analysis combined with data from literature and previous work produced a panel of putative PCa progression markers, which were used in a transcriptomic analysis of 29 radical prostatectomy samples and correlated with clinical outcome.
resultsStatistical analysis yielded seven putative markers of PCa progression, ANPEP, ABL1, PSCA, EFNA1, HSPB1, INMT and TRIP13. Two data transformation methods were utilised with only markers that were significant in both selected for further analysis. ANPEP and EFNA1 were significantly correlated with Gleason score. Models of progression co-utilising markers ANPEP and ABL1 or ANPEP and PSCA had the ability to correctly predict indolent or aggressive disease, based on Gleason score, in 89.7% and 86.2% of cases, respectively. Another model of TRIP13 expression in combination with preoperative PSA level and Gleason score was able to correctly predict recurrence in 85.7% of cases.
conclusionThis proof of principle study demonstrates a novel association of carcinogenic and tumourigenic gene expression with PCa stage and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.